EMA401 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-herpetic Neuralgia
Conditions
Post-herpetic Neuralgia
Trial Timeline
Jun 27, 2017 → Mar 7, 2019
NCT ID
NCT03094195About EMA401 + Placebo
EMA401 + Placebo is a phase 2 stage product being developed by Novartis for Post-herpetic Neuralgia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03094195. Target conditions include Post-herpetic Neuralgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03297294 | Phase 2 | Terminated |
| NCT03094195 | Phase 2 | Terminated |
Competing Products
5 competing products in Post-herpetic Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 52 |
| pregabalin | Pfizer | Approved | 84 |
| BMS-954561 + BMS-954561 + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| HSK16149，probenecid, cimetidine | Haisco Pharmaceutical Group | Phase 1 | 30 |